FLT3 and acute myeloid leukemia: As shown in Fig. 1c, the addition of venetoclax to midostaurin or gilteritinib exhibited synergism in the FLT3-ITD cell lines MOLM-13 and MV4-11, while limited to absent synergism was observed in FLT3 wild-type (WT) AML cell lines (Additional file 1: Fig. S1A).